Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 48%
Buy 38%
Hold 10%
Sell 5%
Strong Sell 0%

Bulls say

DexCom is poised for significant growth driven by strategic Medicare expansions and additional coverage wins in the NIT segment, which are expected to expand the number of covered lives and provide upside potential. The company has a strong product pipeline, highlighted by the improved G7 continuous glucose monitoring systems, which are fostering increased adoption and usage among diabetic patients. Furthermore, the anticipated operational leverage and gross margin expansion from transitioning to 15-day sensors support a forecast of mid-teens revenue growth and over 20% EPS growth through 2028.

Bears say

DexCom reported sensor revenue of $1.18 billion, reflecting a year-over-year growth of 20%, but hardware revenue fell significantly by 31%, underscoring a potential weakness in product demand. Furthermore, the company's guidance for fiscal year 2026 suggests a revenue range of $5.16 billion to $5.25 billion, which is slightly below consensus expectations, indicating a trend of decelerating sales as the mix shifts towards pharmacy distribution. Amidst these financial challenges, DexCom's recent acknowledgment of a decelerating growth trend and execution issues suggests that its stock may continue to face downward pressure compared to competitors.

DexCom (DXCM) has been analyzed by 21 analysts, with a consensus rating of Buy. 48% of analysts recommend a Strong Buy, 38% recommend Buy, 10% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 21 analysts, DexCom (DXCM) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.